NURSE NETWORK
Welcome to the ViiV UK Nurse Network. You asked, we listened. Here we have included useful resources for Vocabria▼(cabotegravir) and Rekambys▼(rilpivirine) long-acting injectables for nurses written by nurses.
Nurses are key in developing and managing the delivery of Vocabria and Rekambys for people living with HIV. They know people well, spending more time with them and therefore gaining a deep meaningful understanding of their medical & psychosocial needs.
UK nurses have developed useful resources, which include:
- Top tips of implementing Vocabria and Rekambys: bringing to life how UK nurses run their HIV injectable service considering what has worked well as where there is room for improvement.
- Case studies which show people's experience on Vocabria and Rekambys and also demonstrate the nurses’ role in patient identification.
Hopefully these resources resonate with you as they show what is happening with real people in the UK. They are also representative of different areas of the UK, in both small and large clinic-settings, and also within the community. We hope you enjoy reading the content and that they support you with implementation of your own injectable HIV service.
Send us your feedback and suggestions,
Email us any feedback or suggestions on what you would like to see from the Nurse Network in future. Once you have submitted this, we at ViiV Healthcare UK will review and take onboard for future!
REKAMBYS (rilpivirine long-acting injection), including the trademark is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned by the ViiV
Healthcare group
PM-GB-CBR-WCNT-230011 | February 2024
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.